| scholarly article | Q13442814 |
| P50 | author | Todd Golub | Q7812388 |
| Andrew L. Kung | Q38544548 | ||
| Stephen P. Finn | Q40115968 | ||
| Phioanh Nghiemphu | Q59440413 | ||
| T.A. Lewis | Q67474605 | ||
| Karl R. Clauser | Q73148814 | ||
| D R Mani | Q79954342 | ||
| Rameen Beroukhim | Q88043871 | ||
| P2093 | author name string | Bina Julian | |
| Jinyan Du | |||
| Massimo Loda | |||
| Steven A Carr | |||
| Haley Hieronymus | |||
| David N Louis | |||
| Ingo K Mellinghoff | |||
| Linda M Liau | |||
| Xiao P Peng | |||
| Rebecca L Maglathlin | |||
| Paula Bernasconi | |||
| Melissa Burns | |||
| P2860 | cites work | Immunoaffinity profiling of tyrosine phosphorylation in cancer cells | Q21735929 |
| Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Structural organization of the bcr gene and its role in the Ph' translocation | Q28286576 | ||
| Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs | Q28609614 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma | Q30014823 | ||
| Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 | ||
| Src family kinases, key regulators of signal transduction | Q30434839 | ||
| Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas | Q33881165 | ||
| Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases | Q33906140 | ||
| Brain tumour stem cells | Q36488721 | ||
| Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. | Q36841179 | ||
| A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. | Q37089440 | ||
| Reduced glioma infiltration in Src-deficient mice | Q39010683 | ||
| Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. | Q39985982 | ||
| Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines | Q40063867 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways | Q40236461 | ||
| SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. | Q40488530 | ||
| STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications | Q40783216 | ||
| Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. | Q42528145 | ||
| Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. | Q45198729 | ||
| Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme | Q45723594 | ||
| Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin | Q48536258 | ||
| NDF/heregulin stimulates the phosphorylation of Her3/erbB3 | Q72093770 | ||
| P433 | issue | 1 | |
| P921 | main subject | phosphorylation | Q242736 |
| glioblastoma | Q282142 | ||
| P304 | page(s) | 77-83 | |
| P577 | publication date | 2008-12-21 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy | |
| P478 | volume | 27 |
| Q67228086 | A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-]Pyrimidine Dual Src/P-Glycoprotein Inhibitor |
| Q34797435 | A Novel Phosphopeptide Microarray Based Interactome Map in Breast Cancer Cells Reveals Phosphoprotein-GRB2 Cell Signaling Networks |
| Q41325859 | A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK. |
| Q30981853 | A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells |
| Q30579545 | A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype. |
| Q33742159 | A chemical and phosphoproteomic characterization of dasatinib action in lung cancer |
| Q38262123 | A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. |
| Q36300039 | A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins |
| Q27851660 | A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors |
| Q35176386 | A pharmacogenomic method for individualized prediction of drug sensitivity |
| Q35263202 | A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. |
| Q37623870 | Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss |
| Q36799036 | Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells |
| Q35964699 | Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers |
| Q38010802 | Antiangiogenic therapies in glioblastoma multiforme |
| Q38194417 | Application of molecular technologies for phosphoproteomic analysis of clinical samples |
| Q49720489 | Autophosphorylation of the C-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants |
| Q92159343 | Big Data Approaches for Modeling Response and Resistance to Cancer Drugs |
| Q28829017 | Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases |
| Q34658293 | Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study |
| Q36684373 | Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling |
| Q36081300 | Caspase-8 expression and its Src-dependent phosphorylation on Tyr380 promote cancer cell neoplastic transformation and resistance to anoikis |
| Q60928004 | Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in Glioblastoma |
| Q39142075 | Cell‐Based Proteome Profiling Using an Affinity‐Based Probe (AfBP) Derived from 3‐Deazaneplanocin A (DzNep) |
| Q35408594 | Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma |
| Q92019790 | Conjugation of Dasatinib with MHI-148 Has a Significant Advantageous Effect in Viability Assays for Glioblastoma Cells |
| Q39672915 | Connexin43 inhibits the oncogenic activity of c-Src in C6 glioma cells |
| Q92290287 | Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo |
| Q41266999 | Connexin43 recruits PTEN and Csk to inhibit c-Src activity in glioma cells and astrocytes |
| Q96338968 | Crk1/2 and CrkL play critical roles in maintaining podocyte morphology and function |
| Q30009513 | Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics. |
| Q45013403 | Dasatinib in recurrent glioblastoma: failure as a teacher |
| Q34264571 | Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. |
| Q41907332 | Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells |
| Q37613072 | Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors |
| Q35957518 | Discoidin domain receptor tyrosine kinases: new players in cancer progression |
| Q39383476 | EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment |
| Q38199643 | EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. |
| Q33403967 | EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma |
| Q37610324 | Emerging affinity-based techniques in proteomics |
| Q35914897 | Emerging insights into the molecular and cellular basis of glioblastoma |
| Q37344321 | Enhanced Detection of Multiply Phosphorylated Peptides and Identification of Their Sites of Modification |
| Q36520705 | Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. |
| Q36299576 | Functions of the Lyn tyrosine kinase in health and disease |
| Q37406548 | Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients |
| Q28535249 | Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer |
| Q45877715 | Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers |
| Q34182724 | HIF-1 and c-Src mediate increased glucose uptake induced by endothelin-1 and connexin43 in astrocytes |
| Q23058134 | High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines |
| Q24646409 | Identifying druggable disease-modifying gene products |
| Q37479213 | Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. |
| Q38705548 | Inferring Intracellular Signal Transduction Circuitry from Molecular Perturbation Experiments |
| Q33950522 | Integration and analysis of genome-scale data from gliomas |
| Q39652400 | Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. |
| Q33992432 | Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines |
| Q38832513 | Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma |
| Q24648828 | Latent bone metastasis in breast cancer tied to Src-dependent survival signals |
| Q24299210 | Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism |
| Q28771755 | Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming |
| Q39210492 | Molecular Dissection of AKT Activation in Lung Cancer Cell Lines |
| Q33911283 | Molecular targeting of glioblastoma: Drug discovery and therapies |
| Q49870857 | Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins |
| Q27851720 | Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer |
| Q37049816 | Network Modeling Identifies Patient-specific Pathways in Glioblastoma. |
| Q30361219 | Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. |
| Q34017103 | New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells |
| Q34121339 | Novel dual Src/Abl inhibitors for hematologic and solid malignancies |
| Q37789177 | Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas |
| Q58696684 | Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors |
| Q28253621 | PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling |
| Q36782617 | PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling |
| Q38888799 | PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor. |
| Q35021359 | Pathway inhibition: emerging molecular targets for treating glioblastoma |
| Q36949546 | Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma |
| Q35070978 | Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. |
| Q92838396 | Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma |
| Q39434337 | Phosphoproteomic studies of receptor tyrosine kinases: future perspectives |
| Q42512195 | Phosphorylation of the C-Raf N-region promotes Raf dimerization |
| Q57969203 | Plasmonic micro-beads for fluorescence enhanced, multiplexed protein detection with flow cytometry |
| Q38926034 | Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma |
| Q37209222 | Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions |
| Q52725375 | Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation. |
| Q50129409 | Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma |
| Q24632928 | Recent advances in the molecular understanding of glioblastoma |
| Q39465446 | Receptor Tyrosine Kinase Inhibitor Profiling Using Bead-Based Multiplex Sandwich Immunoassays |
| Q89604993 | Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion |
| Q36212896 | Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. |
| Q39640693 | Role of lymphocyte-specific protein tyrosine kinase (LCK) in the expansion of glioma-initiating cells by fractionated radiation |
| Q37952242 | Role of tyrosine kinase inhibitors in the management of high-grade gliomas |
| Q38927421 | SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment |
| Q34320767 | Sequential Multiplex Analyte Capturing for Phosphoprotein Profiling |
| Q35673598 | Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells |
| Q42736814 | Snapshots of protein dynamics and post-translational modifications in one experiment--beta-catenin and its functions |
| Q37481145 | Src controls castration recurrence of CWR22 prostate cancer xenografts |
| Q36218089 | Src family kinases differentially influence glioma growth and motility |
| Q24289429 | Studying Cellular Signal Transduction with OMIC Technologies |
| Q39526503 | TGF-β signaling is required for maintenance of retinal ganglion cell differentiation and survival |
| Q39196241 | TSC1 involvement in bladder cancer: diverse effects and therapeutic implications |
| Q37597360 | Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. |
| Q37533648 | Targeted therapy for malignant glioma patients: lessons learned and the road ahead |
| Q38186656 | Targeted therapy in gliomas |
| Q50501834 | Targeting Lyn tyrosine kinase through protein fusions encompassing motifs of Cbp (Csk-binding protein) and the SOCS box of SOCS1. |
| Q35539318 | Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies |
| Q34606869 | Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion |
| Q39650793 | The Adaptor Protein TRIP6 Antagonizes Fas-Induced Apoptosis but Promotes Its Effect on Cell Migration |
| Q36832243 | The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo |
| Q38940817 | The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion |
| Q37080936 | The current state of the art of quantitative phosphoproteomics and its applications to diabetes research |
| Q33521423 | The kinase Mirk is a potential therapeutic target in osteosarcoma |
| Q38995896 | The role of Src family kinases in growth and migration of glioma stem cells. |
| Q24616659 | The role of Src in solid tumors |
| Q56474264 | Thiazoles in Peptides and Peptidomimetics |
| Q33655352 | Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib |
| Q37890867 | Towards systematic functional characterization of cancer genomes |
| Q37815132 | Tracing the origins of metastasis |
| Q37349865 | Transcriptional regulatory circuits: predicting numbers from alphabets |
| Q37412022 | Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation |
| Q29617359 | Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion |
| Q58582584 | Upconversion Nanoparticles-Encoded Hydrogel Microbeads-Based Multiplexed Protein Detection |
| Q37423918 | Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma |
| Q31138564 | Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases |
| Q37779884 | Validating cancer drug targets through chemical genetics |
| Q47578254 | Versatile design and synthesis of nano-barcodes |
| Q24306274 | β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis |
Search more.